521 related articles for article (PubMed ID: 35667775)
1. Estimating Cost-Effectiveness Using Alternative Preference-Based Scores and Within-Trial Methods: Exploring the Dynamics of the Quality-Adjusted Life-Year Using the EQ-5D 5-Level Version and Recovering Quality of Life Utility Index.
Franklin M; Hunter RM; Enrique A; Palacios J; Richards D
Value Health; 2022 Jun; 25(6):1018-1029. PubMed ID: 35667775
[TBL] [Abstract][Full Text] [Related]
2. Psychometric assessment of EQ-5D-5L and ReQoL measures in patients with anxiety and depression: construct validity and responsiveness.
Franklin M; Enrique A; Palacios J; Richards D
Qual Life Res; 2021 Sep; 30(9):2633-2647. PubMed ID: 33835414
[TBL] [Abstract][Full Text] [Related]
3. Enabling QALY estimation in mental health trials and care settings: mapping from the PHQ-9 and GAD-7 to the ReQoL-UI or EQ-5D-5L using mixture models.
Franklin M; Hernández Alava M
Qual Life Res; 2023 Oct; 32(10):2763-2778. PubMed ID: 37314661
[TBL] [Abstract][Full Text] [Related]
4. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
Yang F; Devlin N; Luo N
Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
[TBL] [Abstract][Full Text] [Related]
5. Comparing the EQ-5D-5L crosswalks and value sets for England, the Netherlands and Spain: Exploring their impact on cost-utility results.
Ben Â; Finch AP; van Dongen JM; de Wit M; van Dijk SEM; Snoek FJ; Adriaanse MC; van Tulder MW; Bosmans JE
Health Econ; 2020 May; 29(5):640-651. PubMed ID: 32059078
[TBL] [Abstract][Full Text] [Related]
6. Measuring health-related quality of life and well-being: a head-to-head psychometric comparison of the EQ-5D-5L, ReQoL-UI and ICECAP-A.
Xu RH; Keetharuth AD; Wang LL; Cheung AW; Wong EL
Eur J Health Econ; 2022 Mar; 23(2):165-176. PubMed ID: 34338898
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions.
Shaw JW; Bennett B; Trigg A; DeRosa M; Taylor F; Kiff C; Ntais D; Noon K; King MT; Cocks K
Value Health; 2021 Nov; 24(11):1651-1659. PubMed ID: 34711366
[TBL] [Abstract][Full Text] [Related]
8. Assessing the Impact of EQ-5D Country-specific Value Sets on Cost-utility Outcomes.
van Dongen JM; Jornada Ben Â; Finch AP; Rossenaar MMM; Biesheuvel-Leliefeld KEM; Apeldoorn AT; Ostelo RWJG; van Tulder MW; van Marwijk HWJ; Bosmans JE
Med Care; 2021 Jan; 59(1):82-90. PubMed ID: 33201085
[TBL] [Abstract][Full Text] [Related]
9. BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.
Shaw L; Rodgers H; Price C; van Wijck F; Shackley P; Steen N; Barnes M; Ford G; Graham L;
Health Technol Assess; 2010 May; 14(26):1-113, iii-iv. PubMed ID: 20515600
[TBL] [Abstract][Full Text] [Related]
10. A (five-)level playing field for mental health conditions?: exploratory analysis of EQ-5D-5L-derived utility values.
Camacho EM; Shields G; Lovell K; Coventry PA; Morrison AP; Davies LM
Qual Life Res; 2018 Mar; 27(3):717-724. PubMed ID: 29248995
[TBL] [Abstract][Full Text] [Related]
11. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
Moore A; Young CA; Hughes DA
Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the PROMIS Preference Score (PROPr) and EQ-5D-5L Index Value in General Population Samples in the United Kingdom, France, and Germany.
Klapproth CP; Sidey-Gibbons CJ; Valderas JM; Rose M; Fischer F
Value Health; 2022 May; 25(5):824-834. PubMed ID: 35500951
[TBL] [Abstract][Full Text] [Related]
13. SF-6D and EQ-5D result in widely divergent incremental cost-effectiveness ratios in a clinical trial of older women: implications for health policy decisions.
Davis JC; Liu-Ambrose T; Khan KM; Robertson MC; Marra CA
Osteoporos Int; 2012 Jul; 23(7):1849-57. PubMed ID: 21909728
[TBL] [Abstract][Full Text] [Related]
14. Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores?
Barton GR; Sach TH; Jenkinson C; Avery AJ; Doherty M; Muir KR
Health Qual Life Outcomes; 2008 Jul; 6():51. PubMed ID: 18625052
[TBL] [Abstract][Full Text] [Related]
15. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.
Pickard AS; Gooderham M; Hartz S; Nicolay C
J Med Econ; 2017 Jan; 20(1):19-27. PubMed ID: 27471948
[TBL] [Abstract][Full Text] [Related]
16. Comparison of EQ-5D-5L and SPVU-5D for measuring quality of life in patients with venous leg ulcers in an Australian setting.
Cheng Q; Kularatna S; Lee XJ; Graves N; Pacella RE
Qual Life Res; 2019 Jul; 28(7):1903-1911. PubMed ID: 30778889
[TBL] [Abstract][Full Text] [Related]
17. To what extent does the use of crosswalks instead of EQ-5D value sets impact reimbursement decisions?: a simulation study.
Ben ÂJ; van Dongen JM; Finch AP; Alili ME; Bosmans JE
Eur J Health Econ; 2023 Nov; 24(8):1253-1270. PubMed ID: 36371791
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Spironolactone for Adult Female Acne (SAFA): economic evaluation alongside a randomised controlled trial.
Pyne S; Sach TH; Lawrence M; Renz S; Eminton Z; Stuart B; Thomas KS; Francis N; Soulsby I; Thomas K; Permyakova NV; Ridd MJ; Little P; Muller I; Nuttall J; Griffiths G; Layton AM; Santer M
BMJ Open; 2023 Dec; 13(12):e073245. PubMed ID: 38081673
[TBL] [Abstract][Full Text] [Related]
19. Multifactorial falls prevention programme compared with usual care in UK care homes for older people: multicentre cluster randomised controlled trial with economic evaluation.
Logan PA; Horne JC; Gladman JRF; Gordon AL; Sach T; Clark A; Robinson K; Armstrong S; Stirling S; Leighton P; Darby J; Allen F; Irvine L; Wilson ECF; Fox C; Conroy S; Mountain G; McCartney K; Godfrey M; Sims E
BMJ; 2021 Dec; 375():e066991. PubMed ID: 34876412
[TBL] [Abstract][Full Text] [Related]
20. Choice Defines QALYs: A US Valuation of the EQ-5D-5L.
Craig BM; Rand K
Med Care; 2018 Jun; 56(6):529-536. PubMed ID: 29668646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
